SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in BioXcel Therapeutics
Beneficial Ownership Report
Armistice Capital, LLC and its managing member Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed Amendment No. 1 to Schedule 13G regarding their beneficial ownership in BioXcel Therapeutics, Inc.
- As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 288,131 shares of BioXcel Therapeutics, Inc. Common Stock.
- This ownership represents 4.99% of the outstanding class of securities.
- The Reporting Persons hold shared voting power and shared dispositive power over all 288,131 shares.
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine beneficial ownership disclosure filing (Schedule 13G) and does not contain information that would typically indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends from, or proceeds from the sale of, the reported securities. Armistice Capital, LLC is the investment manager for this fund.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant ownership stake held by an institutional investor and its managing member, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (end of reporting period) |
| 05/15/2025 | Date of filing |
Keywords
BioXcel Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.